Company profile: Castle Biosciences
1.1 - Company Overview
Company description
- Provider of molecular and genomic diagnostic tests for cancer, including DecisionDx-Melanoma for risk of recurrence, metastasis and sentinel lymph node positivity in cutaneous melanoma; DecisionDx-SCC for nodal or distant metastasis risk in SCC; TissueCypher to predict progression to esophageal cancer in Barrett’s esophagus; DecisionDx-UM for metastatic risk in uveal melanoma; and IDgenetix to guide personalized mental health medication selection.
Products and services
- DecisionDx-SCC: A genomic, 40-gene assay that stratifies nodal and distant metastasis risk in squamous cell carcinoma patients by interrogating the biological profile of their tumor tissue
- DecisionDx-Melanoma: A gene expression–based assay that delivers personalized risk assessments for recurrence, metastasis, and sentinel lymph node positivity in patients with cutaneous melanoma
- DecisionDx-UM: A comprehensive molecular profiling assay used to evaluate metastatic risk in patients diagnosed with uveal melanoma
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Castle Biosciences
Abeona Therapeutics
HQ: United States
Website
- Description: Provider of gene and cell therapy R&D for rare genetic diseases, including Sanfilippo syndrome types A and B; Recessive Dystrophic Epidermolysis Bullosa (pz-cel, EB-101); and preclinical gene therapies ABO-503 for X-Linked Retinoschisis, ABO-504 for Stargardt Disease, ABO-505 for Autosomal Dominant Optic Atrophy; plus UX111 for MPS IIIA in partnership with Ultragenyx Pharmaceutical Inc.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Abeona Therapeutics company profile →
CTI BioPharma
HQ: United States
Website
- Description: Provider of biopharmaceutical oncology products for cancer treatment, focused on blood-related cancers. Develops, acquires, and commercializes therapies including Pixantrone (Phase III; non-Hodgkin's lymphoma), Brostallicin (first-line Phase II; sarcoma), and OPAXIO chemotherapeutic.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full CTI BioPharma company profile →
Smart Therapeutics
HQ: United States
Website
- Description: Provider of biopharmaceutical drug discovery and development focused on orally administered drugs.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Smart Therapeutics company profile →
Tavotek Biotherapeutics
HQ: United States
Website
- Description: Provider of therapeutic medicine discovery, development and commercialization, with platforms and programs including TavoSelect phage display to discover diversified human antibody sequences for biologics and diagnostics; TavoPrecise to develop optimized mono- and multi-specific biologics; TavoELITE to address intracellular undruggable targets; and oncology and immunology therapeutics for cancer, inflammatory and allergic diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Tavotek Biotherapeutics company profile →
PreventionGenetics
HQ: United States
Website
- Description: Provider of comprehensive genetic testing services, including whole-genome (PGnome) and whole-exome (PGxome) sequencing; targeted panels across endocrinology, hematology, and immunology; and Sanger sequencing, aCGH, and MLPA to detect and confirm genetic variants, deletions, and duplications across nearly all clinically relevant genes.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full PreventionGenetics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Castle Biosciences
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Castle Biosciences
2.2 - Growth funds investing in similar companies to Castle Biosciences
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Castle Biosciences
4.2 - Public trading comparable groups for Castle Biosciences
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →